BlackRock Amends Sutro Biopharma Stake, Maintains Significant Position
Ticker: STRO · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1382101
| Field | Detail |
|---|---|
| Company | Sutro Biopharma, Inc. (STRO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biopharma
TL;DR
**BlackRock updated its Sutro Biopharma holdings, still a big player.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating a change in its ownership of SUTRO BIOPHARMA, INC. common stock as of December 31, 2023. This amendment, the third for BlackRock, shows that the investment giant continues to hold a significant stake in Sutro Biopharma. For investors, this signals BlackRock's ongoing confidence (or at least continued investment) in Sutro Biopharma, a biotechnology company, which can be a positive indicator of institutional interest.
Why It Matters
This filing shows that a major institutional investor, BlackRock, still holds a substantial position in Sutro Biopharma, which can influence market perception and liquidity for the stock.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued institutional presence in Sutro Biopharma, but this filing alone doesn't provide enough detail to warrant a specific buy/sell action. It's a data point for broader due diligence.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- SUTRO BIOPHARMA, INC. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- BlackRock will continue to hold a significant, but potentially fluctuating, stake in Sutro Biopharma. (BlackRock Inc.) — medium confidence, target: Q1 2025
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3)' sections.
Who is the reporting entity in this filing?
The reporting entity is BlackRock Inc., as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.
What is the subject company whose shares are being reported?
The subject company is SUTRO BIOPHARMA, INC., as stated under the 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SUTRO BIOPHARMA, INC.' section.
What was the date of the event that triggered this filing?
The date of the event which requires the filing of this statement was December 31, 2023, as specified in the filing.
What is the CUSIP number for the securities discussed in this filing?
The CUSIP number for the Common Stock of SUTRO BIOPHARMA, INC. is 869367102, as listed in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding SUTRO BIOPHARMA, INC. (STRO).